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Over the recent past, the importance of aberrant immune cell activation as one of the
contributing mechanisms to the development of insulin-resistance and type 2 diabetes
(T2D) has been recognized. Among the panoply of pro-inflammatory cytokines that are
linked to chronic metabolic diseases, new data suggests that interleukin-1β (IL-1β) may
play an important role in initiating and sustaining inflammation-induced organ dysfunction
in T2D. Therefore, factors that control secretion of bioactive IL-1β have therapeutic
implications. In this regard, the identification of multiprotein scaffolding complexes,
“inflammasomes,” has been a great advance in our understanding of this process.
The secretion of bioactive IL-1β is predominantly controlled by activation of caspase-1
through assembly of a multiprotein scaffold, “inflammasome” that is composed of NLRP3
(nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) ASC
(apoptosis associated speck-like protein containing a CARD) and procaspase-1. The
NLRP3 inflammasome appears to be an important sensor of metabolic dysregulation
and controls obesity-associated insulin resistance and pancreatic beta cell dysfunction.
Initial clinical “proof of concept” studies suggest that blocking IL-1β may favorably
modulate factors related to development and treatment of T2D. However, this potential
therapeutic approach remains to be fully substantiated through phase-II clinical studies.
Here, we outline the new immunological mechanisms that link metabolic dysfunction
to the emergence of chronic inflammation and discuss the opportunities and challenges
of future therapeutic approaches to dampen NLRP3 inflammasome activation or IL-1β
signaling for controlling type 2 diabetes.
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INTRODUCTION
With a disease rate of 8.3% and cost of $174 billion, there is
no debate that diabetes is a highly prevalent and costly life-
long disease (Dall et al., 2010; Centers for Disease Control and
Prevention, 2011). Whereas type 1 diabetes is characterized by
autoimmune destruction of pancreatic islets, Type 2 diabetes
(T2D) has been described as an autoinflammatory disorder, char-
acterized first by insulin resistance in peripheral tissues followed
by beta cell failure, including decreased islet size and insulin
production (McGonagle and McDermott, 2006).
T2D is clearly associated with obesity, and clinical progression
of this disease has been linked to chronic low-grade inflamma-
tion due to activation of immune cells. However, up until recently,
the identity of specific immunological sensors that are trig-
gered in response to metabolic dysfunction to produce a state of
inflammation was not fully understood. The underlying clinical
rationale to identify the immunological triggers of metabolically
driven inflammation has been to develop approaches to thera-
peutically target the immune sensors and break the feed-forward
cycle of organ dysfunction and development of diabetes. Among
several sites of inflammation in metabolic diseases, adipose tissue
is a large contributor to circulating proinflammatory cytokines
during obesity. Initially, tumor necrosis factor-α (TNFα) was
considered a possible therapeutic target because its adipose tis-
sue expression was increased in multiple rodent-obesity models
and TNFα decreased insulin signaling in insulin sensitive tissues
(Hotamisligil et al., 1993, 1994a,b; Hotamisligil and Spiegelman,
1994). Accordingly, Tnf mRNA expression was shown to be
increased in adipose tissue of obese hyperinsulinemic human
subjects (Hotamisligil et al., 1995). Furthermore, weight loss-
induced improvement in insulin-sensitivity was associated with
reduction in TNF suggesting that this pro-inflammatory cytokine
impairs insulin-action. (Hotamisligil et al., 1995). Consistent
with these clinical findings, mechanistic studies using Tnf α
gene knockout mice or neutralization of TNF with antibodies
improved glycemia in obese mice and rats, respectively, mak-
ing it a potential therapeutic target for T2D (Hotamisligil et al.,
1994a; Uysal et al., 1997). Despite overwhelming evidence in
favor of TNF having a critical role in regulating inflamma-
tion and insulin-action (Hotamisligil et al., 1993, 1994a,b, 1995;
Hotamisligil and Spiegelman, 1994; Peraldi et al., 1996; Uysal
et al., 1997; Liu et al., 1998), the translation of basic research
findings with TNF targeted neutralization approaches to diabetes
care in humans has had disappointing results with both acute
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and chronic treatment (Ofei et al., 1996; Paquot et al., 2000;
Di Rocco et al., 2004; Wascher et al., 2011). Further studies
to enhance the delivery and tissue availability of TNF targeted
treatments are being pursued to improve treatment outcomes.
Here, we discuss clinically relevant, novel “inflammasome” mech-
anisms that regulate interleukin-1β (IL-1β) and IL-18 driven
pro-inflammatory cascades. We discuss the current experimen-
tal evidence and potential future therapeutic strategies to target
the “inflammasome” pathway in prevention and treatment of
diabetes.
THE NLRP3 INFLAMMASOME REGULATES IL-1β SECRETION
DURING METABOLIC STRESS
Given the recent developments in understanding inflamma-
tion as a mediator of disease progression, an understanding
of factors related to IL-1β regulation is in order. IL-1β is
a proinflammatory cytokine that is implicated in the patho-
genesis of many inflammatory diseases including diabetes,
rheumatoid arthritis and genetic auto-inflammatory disorders
(Dinarello, 2011). Although IL-1β is produced by many cell
types, it is predominately produced by monocytes, macrophages,
and neutrophils (Dinarello, 2011). While most cytokines are
regulated at the transcriptional (gene regulation) level, IL-1β
is further regulated at the protein level, being stored as an
inactive pro-form, which must be cleaved by the IL-1β pro-
cessing cysteine protease, caspase-1 (Figure 1) for its secre-
tion and activation (Dinarello, 2011). As an additional level
of control, caspase-1 is also stored in an inactive state which
in turn is activated within large cytosolic multiprotein com-
plexes termed “inflammasomes” upon receiving specific signals
(Schroder and Tschopp, 2010). Classically, the inflammasome
driven caspase-1 activation and IL-1β secretion occurs as innate
immune cells like macrophages engulf bacterial, fungal, and
viral proteins. The inflammasome activation is therefore a
vital immune response to protect the host against numerous
pathogens (Schroder and Tschopp, 2010). Interestingly, new evi-
dence suggest that inflammasome activation may be important
in chronic diseases such as obesity and diabetes where low
FIGURE 1 | NLRP3 inflammasome activation during type II
diabetes. The NLRP3 inflammasome is composed of NLRP3, ASC,
and procaspase-1. During type II diabetes there is increased
accumulation of endogenous danger-associated molecular patterns
(ceramides, free cholesterol, etc.) which are sensed by the NLRP3
inflammasome. After sensing of DAMPs, inflammasome assembly
occurs by interactions in the protein domains of NLRP3 ASC and
procaspase-1. This leads to caspase-1 activation and the secretion of
bioactive IL-1β and IL-18, which go on to cause insulin resistance
and organ dysfunction.
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grade inflammation occurs without overt infection (Schroder and
Tschopp, 2010).
The NLRP3 inflammasome is formed through the interaction
of several cellular proteins. As demonstrated, these key pro-
teins are identified as NLRP3 (for nucleotide-binding domain,
leucine-rich-containing family, pyrin domain-containing-3) ASC
(apoptosis associated speck-like protein containing a CARD), and
procaspase-1 (Figure 1). NLRP3 is expressed predominantly in
circulating monocytes and tissue macrophages (Guarda et al.,
2011). The NLRP3 inflammasome components contain con-
served protein domains and interaction of these domains on
inflammasome proteins (i.e., homotypic protein–protein interac-
tions) leads to inflammasome assembly. Thus, the pyrin domain
of NLRP3 interacts with the pyrin domain of ASC, and the
CARD (caspase activation recruitment domain) of ASC inter-
acts with the CARD domain of procaspase-1 (Figure 1). In
this way, the NLRP3 inflammasome is formed leading to the
cleavage of procaspase-1 to its enzymatically activated form
(Figure 1).
Activation of the NLRP3 inflammasome by bacteria that pro-
duce pore forming toxins (Mariathasan et al., 2006), viruses
(Muruve et al., 2008; Allen et al., 2009), and fungi (Gross
et al., 2009) and the resultant release of IL-1β and IL-18 plays
a critical role in host defense. Interestingly, the NLRP3 inflam-
masome can also be activated in response to accumulation of
endogenous damage associated molecular patterns (DAMPs) that
are of non-microbial origin and cause “sterile inflammation”
(Figure 1). NLRP3 inflammasome activating metabolic “danger
signals” include, urate, cholesterol crystals, extracellular ATP, cer-
tain fatty acids and islet amyloid peptides (Figure 1). Growing
recognition of the NLRP3 inflammasome pathway in triggering
sterile inflammation, i.e., inflammation of non-infectious origin
has put this innate immune sensor at the crossroads of metabolic
disease and inflammation (Wen et al., 2012).
The accumulation of DAMPs during chronic inflammatory
diseases is hypothesized to contribute to systemic inflammation
and disease pathogenesis. During the pathogenesis of T2D, the
NLRP3 inflammasome has been proposed to sense and mediate
downstream inflammatory events of “glucotoxicity” (Zhou et al.,
2010), islet amyloid polypeptide (Masters et al., 2010), lipid inter-
mediates (i.e., ceramides) (Vandanmagsar et al., 2011), and fatty
acids (Wen et al., 2011). The mechanism of inflammasome acti-
vation that links these events remains ambiguous, but it may be
that these danger signals converge on similar signaling pathways
resulting in inflammasome activation.
Mitochondrial damage may be the common pathway between
these stimuli because reactive oxygen species appear to be
necessary for NLRP3 inflammasome activation, and changes
in the redox state of the cell may be a common media-
tor between danger signals and inflammasome activation (Jin
and Flavell, 2010). Treatment of macrophages with LPS and
ATP leads to increased reactive oxygen species, mitochon-
drial damage, and release of mtDNA, a DAMP, into the
cytosol (Nakahira et al., 2011). Although mitochondrial DNA
is sensed by the AIM2 inflammasome, it also serves as a
co-activator of caspase-1 in conjunction with NLRP3 activa-
tion by LPS and ATP (Nakahira et al., 2011). Autophagy,
a process by which cells remove damaged organelles, buffers
inflammasome activation by removing damaged mitochondria,
and limiting ROS production and mtDNA escape into the
cytosol, and is activated by NLRP3 inflammasome activators
(Shi et al., 2012). Moreover, the inflammasome components
NLRP3 and ASC are ubiquitinated and subsequently degraded
by autophagy, and pro-IL-1β is degraded by autophagy as well
(Harris et al., 2011; Shi et al., 2012). Thus, there is a com-
plex interplay between autophagic maintenance of mitochon-
dria and inflammasome proteins that controls inflammasome
activation.
Activated caspase-1 proceeds to cleave pro-IL-1β, pro-IL-18,
and other undefined substrates. IL-1β signaling then occurs
through the IL-1 receptor I (IL1R1), and leads to the acti-
vation of the transcription factor nuclear factor-Kappa-Beta
(NFkB) and the expression of inflammatory genes (Figure 1)
Though lymphocytes are considered a primary target of IL-1β
and IL-18, the receptors for both these inflammasome-dependent
cytokines are ubiquitously expressed in many different types
of cells and tissues, including high expression in pancreatic
islets (Boni-Schnetzler et al., 2009). IL-1β signaling is inhib-
ited by IL-1 receptor antagonist (IL-1RA) and decoy receptors,
i.e., IL-1R2. Decoy receptors appear to bind IL-1 but do not
cause IL-1 signaling. IL-1 signaling is necessary for the inflam-
matory response, but is highly regulated due to the negative
effects of chronic inflammation to body tissues and organs.
Regulation of IL-1 signaling is maintained in healthy individu-
als, but appears to be elevated during chronic proinflammatory
disease states, which makes this pathway a valuable therapeutic
target in T2D.
REDUCED NLRP3 INFLAMMASOME ACTIVATION INCREASES
INSULIN SENSITIVITY AND IMPROVES GLUCOSE
HOMEOSTASIS
The NLRP3 inflammasome, as described in Figure 1, has emerged
as a key regulator of glucose and insulin homeostasis. Specifically,
pre-clinical studies have shown that the genetic deletion of Nlrp3
and Asc in high-fat diet fed mice results in improved glucose tol-
erance and enhanced insulin sensitivity (Stienstra et al., 2011;
Vandanmagsar et al., 2011; Wen et al., 2011). Along with sys-
temic improvements in glucose and insulin homeostasis, the gene
knockout animals, i.e., Nlrp3−/− and Asc−/− have decreased cir-
culating IL-18, and reduced adipose tissue IL-1β, markers of
caspase-1 activation (Vandanmagsar et al., 2011). The pleiotropic
effects of inhibition of NLRP3 inflammasome in obesity are evi-
dent by improved insulin signaling in adipose tissue, liver, and
skeletal muscle and increased insulin secretion in the pancreas
[Figure 2; (Stienstra et al., 2011; Vandanmagsar et al., 2011; Wen
et al., 2011)].
ADIPOSE TISSUE
Adipose is a complex tissue consisting of adipocytes, immune
cells, vasculature, and stromal cells. Macrophages are recruited
to adipose tissue during obesity and represent the largest pop-
ulation of NLRP3 expressing cells in fat (Weisberg et al., 2003).
Recent studies in animal models demonstrate that obesity is
associated with progressive caspase-1 activation in adipose tissue
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FIGURE 2 | The consequences of NLRP3 inflammasome activation
during type II diabetes and possible benefits of NLRP3 and IL-1 targeted
therapies. NLRP3 inflammasome activation during type II diabetes results in
the production of IL-1β and IL-18, which go on to cause insulin resistance and
organ dysfunction in the pancreas, adipose tissue, liver, skeletal muscle, and
circulation. NLRP3 and IL-1β targeted therapy may have potential to reduce
local tissue inflammation and systemic inflammation resulting in systemic
improvement in insulin secretion, insulin sensitivity as well as organ function.
(Vandanmagsar et al., 2011). Consistent with the causal role of
NLRP3 inflammasome activation in the development of inflam-
mation, deletion of Nlrp3 in mice, prevents obesity-induced
caspase-1 activation.
The NLRP3 inflammasome instigates inflammation and
causes leukocytosis (i.e., increased immune cell infiltration) in
visceral adipose tissue during obesity. Consistent with this, the
CD4+ and CD8+ T cell leukocyte sub populations are specifi-
cally reduced in visceral adipose tissue of obese Nlrp3−/− mice
(Vandanmagsar et al., 2011). This reduction in T cells in response
to reduced NLRP3 inflammasome activation is attributable to
a decrease in effector-memory T cell subtype presence in the
adipose tissue (Vandanmagsar et al., 2011). Together with prior
studies, these data suggests that approaches that reduce the
number of activated T cell populations in adipose tissue low-
ers inflammation and improves insulin-action (Feuerer et al.,
2009; Nishimura et al., 2009; Winer et al., 2009; Yang et al.,
2010).
Visceral adipose tissue macrophages isolated from obese
Nlrp3−/− mice have reduced expression of the proinflam-
matory cytokine Tnf-α and chemokines (Ccl20 and Cxcl1)
involved in lymphocyte recruitment. These results demonstrate
the pleiotropic effects of the NLRP3 inflammasome on activa-
tion and recruitment of adipose tissue leukocytes. The functional
consequences of reduced inflammation inNlrp3 and Asc deficient
mice are improved insulin signaling both in fat and other insulin
sensitive tissues (Vandanmagsar et al., 2011; Wen et al., 2011).
Inflammation plays a causal role in insulin resistance, and
in rodent models targeting inflammatory cytokine produc-
tion through genetic and pharmacological approaches results
in improvements in insulin signaling (Olefsky and Glass, 2010;
Kanneganti and Dixit, 2012). After insulin binds to the insulin
receptor, insulin initiates signaling cascades that activate down-
stream pathways, notably PI3K-AKT and the mitogenic MAP
kinase-ERK pathways (Biddinger and Kahn, 2006). In adipose tis-
sue of obeseNlrp3−/− mice, phosphorylation of AKT is enhanced
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indicating greater insulin signaling (Vandanmagsar et al., 2011).
The reduction of IL-1 signaling also improves adipose tissue
insulin sensitivity in a similar way. Adipose tissue explants from
high-fat-fed IL-1 receptor null mice exhibit improved insulin
signaling compared to wild type animals, including increased
glucose transport, AKT phosphorylation, and increased gene
expression of proteins involved with insulin signaling and glu-
cose uptake (Irs-1 and Glut4) (McGillicuddy et al., 2011). These
results demonstrate the strong immune and metabolic conse-
quences of NLRP3 inflammasome activation and IL-1 signaling
during obesity.
Not only does caspase-1 activation influence whole adipose tis-
sue insulin sensitivity, but it may have direct effects on adipocyte
growth, differentiation and metabolism (Stienstra et al., 2010).
Interestingly, human and mouse adipocyte cell lines express the
caspase-1 protein, and its expression is increased over the course
of adipocyte differentiation (Stienstra et al., 2010). Caspase-
1 inhibition results in increased expression of favorable adi-
pogenic (Pparγ) and metabolic markers (Glut4 and adiponectin)
in 3T3-L1 adipocytes (Stienstra et al., 2010). Given low expres-
sion of Nlrp3 and Asc in adipocytes (Vandanmagsar et al., 2011),
the significance of adipocyte-derived IL-1β remains ambigu-
ous because macrophages are the predominant cellular sources
of IL-1β.
Caspase-1 activates multiple protein substrates other than
IL-1β and IL-18, so the exact contribution of downstream medi-
ators of NLRP3 inflammasome activation remains unclear. IL-1β
treated 3T3-L1 adipocytes have reduced capacity to differentiate
into mature adipocytes, and exhibit insulin resistance and reduce
glucose uptake (Lagathu et al., 2006; Jager et al., 2007; Stienstra
et al., 2010). Surprisingly, IL-18 does not appear to have an effect
on 3T3-L1 adipocyte differentiation or the expression of adi-
pogenic genes in spite of its known pro-inflammatory properties
(Stienstra et al., 2010). Given that IL-18 promotes differentiation
of T cells into activated pro-inflammatory T-helper1 (TH1) IFNγ
producing cells (Okamura et al., 1995), it is likely that NLRP3
inflammasome mediated IL-18 secretion induces adipose tissue
inflammation via T cell activation (Vandanmagsar et al., 2011;
Wen et al., 2011).
SKELETAL MUSCLE AND LIVER
Skeletal muscle is a large metabolically active tissue and accounts
for the majority of insulin stimulated glucose disposal. As indi-
cated by improved performance on glucose and insulin tolerance
tests, obese Nlrp3−/− mice exhibit increased skeletal muscle
insulin signaling (Vandanmagsar et al., 2011; Wen et al., 2011).
The effects on skeletal muscle are most likely driven through
decreased adipose tissue and systemic inflammation because there
are not high concentrations of Nlrp3 expressing cells within skele-
tal muscle, however, local macrophages could be influencing this
process.
The liver is also a major contributor to glucose homeosta-
sis by generating glucose through gluconeogenesis. The liver also
becomes insulin resistant during the development of T2D, and
this is associated with increases in the levels of hepatic steato-
sis. IL-1β may contribute to this process, given that cultured
liver cells treated with IL-1β exhibit decreased insulin response
(Nov et al., 2010). Nlrp3−/− and Asc−/− knockout mice exhibit
enhanced liver AKT activation in response to insulin challenge
compared to high-fat fed WT mice (Vandanmagsar et al., 2011;
Wen et al., 2011). Along with improvements of liver insulin sen-
sitivity, obese Nlrp3−/− and Asc−/− mice exhibit reduced hepatic
steatosis compared to wild type controls (Stienstra et al., 2011;
Vandanmagsar et al., 2011). Notably, recent studies also show
that NLRP3 inflammasome is required for the maintenance of gut
epithelial integrity. In response to methionine-choline deficiency
(a model of NASH in mice), NLRP3 inflammasome deficient
animals develop exaggerated fatty liver disease due to microbial
pathogen-associated molecular patterns leakage into the liver via
the portal circulation and activation of the pro-inflammatory
response via the Toll-like receptors 4 and 9 (Henao-Mejia et al.,
2012). In the same study, Asc−/− mice were also noted to have
increased weight gain and glucose intolerance during high fat
feeding, which were reversible upon administration of antibiotics.
This is in contrast with other findings that indicate Asc−/− mice
have increase insulin sensitivity and glucose tolerance (Youm
et al., 2011). T2D has been associated with increased circulating
endotoxin concentration, but it is unclear whether this is cause or
consequence in disease pathogenesis (Pussinen et al., 2011).
NLRP3 INFLAMMASOME AND INSULIN SECRETION
Pancreatic islets, macrophages and dendritic cells may all be
sources of IL-1β in the pancreas. Cultured pancreatic islets are
thought to produce low levels of IL-1β (Arnush et al., 1998).
Macrophages and dendritic cells also reside in the pancreas, and
macrophages are increased in rodent models of T2D and in
patients with T2D (Ehses et al., 2007). It has been shown that
IL-1β treatment alone or in combination with IFN-γ induces
beta cell death in cell culture, although the exact mechanism
by which this occurs is debated (Mandrup-Poulsen et al., 1986;
Collier et al., 2011). Consistent with those results, blocking
IL-1β action on isolated beta cells using IL-1RA (IL-1 receptor
antagonist) improves beta cell survival (Ardestani et al., 2011).
IL-1β production in the pancreas is likely mediated by NLRP3
inflammasome-dependent activation of caspase-1 (Youm et al.,
2011) as also outlined in Figure 1. In support of this concept,
mice that lack NLRP3 inflammasome components (Nlrp3, Asc)
have increased pancreatic islet size in response to chronic high-fat
diet, resulting in increased insulin response to glucose challenge
despite improvements in peripheral insulin sensitivity (Youm
et al., 2011). Additionally, reduction of Nlrp3 inflammasome
activation in chronically obese mice protects the pancreatic beta
cells against cell death (Youm et al., 2011). These findings sug-
gest that reduction in Nlrp3 inflamamsome activity may protect
the pancreatic islet from caspase-1 mediated inflammatory death.
TXNIP may be a crucial mediator connecting beta cell death
and inflammasome activation by linking glucotoxicity and ER
stress to NLRP3 inflammasome activation (Zhou et al., 2010).
Global TXNIP−/− mice recapitulate an insulin sensitive pheno-
type very similar to that of NLRP3 ablation (Yoshihara et al.,
2010). In pancreatic beta cells, TXNIP ablation reduces glucotox-
icity, ER Stress and the subsequent inflammatory and apoptotic
responses (Zhou et al., 2010; Oslowski et al., 2012). TXNIP
serves as a signaling node linking ER stress, IL-1B production
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and beta cell apoptosis. The consequences of pancreatic beta
cell TXNIP and inflammasome activation in vivo are unclear
because beta cell and myeloid cell specific knockouts have not
been used to address this issue. Consistent with the important
role of IL-1β in the pancreas, Il1r1−/− mice that are defi-
cient in IL-1β signaling exhibit improved insulin-secretion in
response to glucose challenge (McGillicuddy et al., 2011). Thus,
lowering Nlrp3 inflammasome activation may protect against
the transition from insulin-resistance to an overt type 2 dia-
betic stage by mechanisms that involve protection from loss of
insulin-producing beta cells. It is presently unclear whether per-
sistent Nlrp3 inflammasome activation causes the transition from
insulin-resistance to islet decompensation and development of
overt T2D.
THERAPEUTIC IMPLICATIONS
Initial studies in humans suggest that NLRP3 inflammasome
activation in obesity could be important in development and
treatment of insulin-resistance and diabetes [Figure 2; (Larsen
et al., 2007; Vandanmagsar et al., 2011; Goossens et al., 2012)].
Lee et al. recently published a study on inflammasome activa-
tion in blood monocytes isolated from type 2 diabetic, drug naive
patients (n = 47) and healthy controls (n = 57) (Lee et al., 2013).
This study determined that both during basal and inflammasome
activating conditions (stimulation with free fatty acids, ATP, or
urate) blood monocytes from patients with T2D have greater
caspase-1 activation and secretion of the caspase-1 activated pro-
teins, IL-1β and IL-18. Inflammasome activation can occur in
response to diverse cellular stresses including reactive oxygen
species, the unfolded protein response and altered autophagy.
In the context of this experiment, hyperglycemia in these T2D
patients resulted in elevated ROS production and greater inflam-
masome activation. Knockdown of ASC or NLRP3 using RNA
interference abrogated the response to DAMPs demonstrat-
ing specificity to this pathway in T2D patients (Lee et al.,
2013). This study provides evidence that the Nlrp3 inflamma-
some activation in T2D patients contributes toward the chronic
pro-inflammatory state.
Gossens et al. designed a study to assess the gene expres-
sion of Nlrp3 and T-cell markers in subcutaneous adipose tis-
sue from lean and obese subjects, and to determine if these
genes were associated with glucose homeostasis measured by
the hyperinsulinemic-euglycemic clamp (Goossens et al., 2012).
Obese subjects had increased body weight, body fat%, adipocyte
diameter, fasting glucose, and insulin and glucose infusion
rate during the hyperinsulinemic-euglycemic clamp test. The
expression of cellular markers of inflammasome activation, i.e.,
Nlrp3, caspase-1, and T cell markers, were positively associated
with increased expression of inflammatory genes. Furthermore,
caspase-1 and Il-18 gene expression, and the ratio of Tbx21/Cd3ε
expression, a marker of pro-inflammatory T-helper 1 cells, were
negatively correlated with glucose infusion rate. Consistent with
relevance of this pathway in diabetes treatment, Il-1β, Nlrp3,
and Asc gene expression is reduced after 1 year of weight loss
in obese type 2 diabetic patients, and these gene expression
changes were positively correlated with improvements in glycemia
(Vandanmagsar et al., 2011). Such associations are further
supported by evidence from human adipose tissue explants that
high glucose levels induce proinflammatory gene expression
(Il-6, Il-8, and Il-1β), increase intracellular pro-IL1β and secre-
tion of bioactive IL-1β (Koenen et al., 2011). Taken together,
these studies indicate that the NLRP3 inflammasome compo-
nents are expressed in human adipose tissue, are responsive
to high glucose concentrations, and associate with markers of
glycemia.
Given the key role of the inflammasome in possibly mediat-
ing many of the factors associated with progression to T2D, and
in control of the condition, it is imperative to test interventions
that may favorably interdict on this system. In humans, there
has been interest in a specific IL-1 receptor antagonist. Anakinra,
IL-1 receptor antagonist, competes with IL-1β for binding to
IL1R1 and has received attention as an agent that may have
efficacy on glycemic control. Larsen et al. conducted a double-
blind, parallel-group trial in which anakinra (n = 34) or placebo
(n = 33) was administered subcutaneously once/day for 13 weeks
(Larsen et al., 2007). The study population were patients with
T2D, >27 body mass index, glycated hemoglobin >7.5% and
had no change in medication type or dose over the course of the
study. As expected, subjects in the anakinra treatment group had
increased circulating IL-1RA concentration compared to placebo,
1256± 958 and 0.6± 0.4μg/L, respectively. Anakinra treatment
resulted in significant reduction in glycated hemoglobin % mea-
sured by the difference between baseline and 4 or 13 weeks
in the treatment versus placebo groups (Larsen et al., 2007).
As reported, at 13 weeks, in the anakinra group, the glycated
hemoglobin level was 0.46% points lower than in the placebo
group (P = 0.03).
To explain changes in glycated hemoglobin concentration,
beta-cell secretory function and insulin sensitivity were measured
at 13 weeks. Anakinra treatment lowered the proinsulin:insulin
ratio and increased C-peptide concentration in response to oral
or intravenous glucose, all measures were presented as change
from baseline. Thus, anakinra treatment increased circulating
IL-1RA and the insulin secretory capacity of the pancreas, but
had no effect on insulin sensitivity. In agreement with no effect
on insulin action, insulin-regulated gene expression in skele-
tal muscle, serum adipokine levels, and body-mass index were
found to be similar in the two study groups. Similar results
were achieved from a study on patients with prediabetes that
showed enhanced beta-cell function during OGTT in response to
anakinra treatment, in the absence of increased insulin sensitivity
(van Asseldonk et al., 2011). Blockade of IL-1 with anakinra does
improve glycemia and beta-cell secretory function and reduces
markers of systemic inflammation.
A follow up study on the diabetics from the Larsen et al.
was performed after the initial anakinra treatment was removed.
Interestingly, this relatively short term (13 weeks) anakinra treat-
ment had long term effects after the treatment was removed.
Thirty-nine weeks after the treatment, the anakinra treated
group had an improved blood proinsulin:insulin ratio, decreased
C-reactive protein and IL-6 concentrations, but no differences in
hemoglobin A1c (Larsen et al., 2009).Within this study there were
responders and non-responders. Responders had lower starting
serum IL-1RA concentrations and a higher group frequency of
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a specific gene polymorphism (SNP rs4251961 allele C), which
is associated with low circulating IL-1RA (Larsen et al., 2009),
indicating that IL-1RA may be beneficial for only specific pop-
ulations. Reduced IL-6 concentrations may also be responsi-
ble for a portion of improvements of pancreatic function with
anakinra treatment in that study. A trial utilizing the IL-6 mono-
clonal antibody Actemra (tocilizumab) during T2D could test this
hypothesis.
In summary, the findings thus far indicated that IL-1 blockade
with specific agents induces improvement of pancreatic insulin
secretory function and reduces markers of systemic inflammation
lasting 39 weeks after treatment withdrawal. Given these results,
it is of interest to speculate that IL-1β specific monoclonal anti-
bodies will have beneficial effects in T2D. Monoclonal antibodies
directed against IL-1β may be favorable compared with anakinra
due to the short half-life of anakinra, which requires daily
injections, and specificity to IL-1β. While anakinra antagonizes
IL-1R1 signaling by both IL-1β and IL-1α, neutralization of IL-1β
through monoclonal antibodies may be favorable because IL-1α
signaling still remains. Intact, IL-1α signaling may also reduce the
efficacy of monoclonal antibodies because inflammasome activa-
tors can cause the secretion of IL-1α in addition to IL-1β (Gross
et al., 2012). Proof of concept for monoclonal antibodies has
been obtained. In a phase 1 study, gevokizumab (XOMA 052),
a monoclonal antibody against IL-1β, showed beneficial effects
on glycemic control and beta-cell function. Specifically, stud-
ies were conducted that evaluated single intravenous infusion or
subcutaneous injection of placebo or IL-1β targeted monoclonal
antibody at 0.01–3.0 or 0.03–0.3mg/kg, respectively. One month
after antibody administration, there were no significant differ-
ences in HbA1c, but at 2 and 3 months a significant reduction was
noted in the intermediate doses (0.03–1.0mg/kg) compared to
the combined low dose (0.01mg/kg) and placebo group (Cavelti-
Weder et al., 2012). As expected, intravenous administration of
gevokizumab resulted in greater circulating antibody concentra-
tions than subcutaneous administration. Subcutaneous delivery
of the 0.03 and 0.3mg/kg antibody doses at day 0, 14, and 28
did not result in a substantial improvement over a single admin-
istration at day 0 alone. It may be that microvascular damage
that occurs during T2D is limiting tissue blood perfusion and for
this reason the circulating antibody concentrations do not reflect
the increased number of doses. A phase 2 trial was done using
gevokizumab in 421 patients, but beneficial effects on glycated
hemoglobin and glycemia were not observed, while reduction in
C-reactive protein was observed (DeGuzman, 2011). The capac-
ity of gevokizumab to improve glucose homeostasis is currently
unclear, but like anakinra it may be effective in specific pop-
ulations. As indicated in the study by Larsen et al., there may
be a subset of the population that responds more favorably to
IL-1β targeted therapy. The stronger effects of anakinra could
be due to inhibition of both IL-1β and IL-1α signaling. It is
important to recognize that inflammation is an ongoing pro-
cess and that IL-1β targeted therapies will reduce inflammation
at the time of administration, but prior inflammatory damage
incurred during the lifespan may not be readily reversible. Thus,
the timing of the intervention may be key to IL-1β targeted ther-
apy and prevention of pancreatic damage may be more useful
than treatment of chronic pancreatic inflammation. Importantly,
given the NLRP3 inflammasome is an upstream activator of
caspase-1 and IL-1, the inhibition of exaggerated NLRP3 inflam-
masome activation by future drugs may have better therapeutic
outcomes in T2D.
Another intriguing question is whether any of the currently
available agents we have at our disposal for use in T2D have any
effect on the inflammasome. The cellular energy sensor, AMPK, is
known to influence caspase-1 activation. As discussed earlier, the
NLRP3 inflammasome is activated by fatty acids, notably palmi-
tate, but this effect is blocked by administration of AICAR, an
AMPK agonist. Metformin is a known AMPK activator and 2m
of metformin treatment reduces NLRP3 inflammasome activa-
tion in peripheral blood mononuclear cells from type 2 diabetic
patients. In addition to metformin, the sulfonylurea glyburide
has been identified as an NLRP3 inflammasome inhibitor, while
other sulfonylurea drugs do not inhibit inflammasome activation
(Lamkanfi et al., 2009). This is an interesting finding consid-
ering the concerns hypoglycemia, weight gain, and secondary
failures with use of sulfonylureas. In certain circumstances, par-
ticularly sepsis, glyburide can act as an anti-inflammatory and
is associated with reduce mortality in lipopolysaccharide chal-
lenged rodents, and observationally in type 2 diabetics with
melioidosis compared to patients with no diabetes (Lamkanfi
et al., 2009; Koh et al., 2011). This effect was limited to gly-
buride treatment and was not associated with either metformin
or insulin treatment. It is presently unclear if the use of gly-
buride at doses lower than those typically used clinically will
have positive effects on beta cell survival and this question
may deserve a more thorough investigation. Compared to IL-1
targeted therapies, glyburide may provide the additional ben-
efit of inhibiting the NLRP3 inflammasome and cleavage of
many caspase-1 substrates. It would be useful to directly assess
the effect of low-dose glyburide on markers of inflammasome
activation in diabetics or pre-diabetics. As discussed above, its
effects may be more useful for the prevention of pancreatic
damage rather than an intervention after damage has already
occurred.
Because IL-1 is important for innate immune signaling, block-
ing its action with IL-1RA could have negative effects on the
immune response. In the study by Larsen et al., there were min-
imal adverse effects of anakinra, with the predominant negative
effect being an increase in injection site reactions (Larsen et al.,
2007). In a larger study of anakinra treatment for rheumatoid
arthritis there was no increase in adverse events besides injection
site reactions (Nuki et al., 2002). IL-1 neutralization may provide
a path to improving pancreatic function, with minimal adverse
effects. However, improvements in drugs targeting this pathway
are required because of the modest effects that have been seen
thus far.
CONCLUSION
IL-1β is an influential immune modulator. Uncontrolled acti-
vation of the NLRP3 inflammasome during disease states and
increased IL-1β synthesis, secretion, and signaling can lead to
inflammatory disease. Initial clinical studies that dampen IL-1β
signaling have shown promise in controlling diabetes but detailed
www.frontiersin.org March 2013 | Volume 4 | Article 50 | 7
Grant and Dixit Inflammasome activation and diabetes development
evidence to support use of IL-1 neutralizing antibodies in dia-
betic patients has thus far not yielded successful results. Notably,
once cleaved, caspase-1 can regulate the activity of several pro-
teins other than just IL-1β and IL-18 (Agard et al., 2010).
New data shows that high-fat diet feeding-induced caspase-1
can deactivate Sirt1 and leads to insulin-resistance (Chalkiadaki
and Guarente, 2012). Activation of Sirt1 by resveratrol and
other small molecules improves glycemic control (Lagouge et al.,
2006; Feige et al., 2008). Thus given inflammasome activa-
tion can impair several metabolically relevant signaling pro-
teins such as Sirt1, additional studies are required to test
whether specific inflammasome or caspase-1 inhibitors offer bet-
ter therapeutic alternatives than IL-1β inhibition as treatment
for diabetes. Considering that the pancreatic damage that occurs
during diabetes is an ongoing inflammatory process that may
not be readily reversible, an early preventive strategy target-
ing NLRP3 inflammasome may prove useful in diabetes and its
complications.
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